Yungjin Pharm. Co., Ltd. (003520.KS)
KRW 1989.0
(-2.02%)
KRW 1989.0
(-2.02%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 3.11 Billion KRW | 142.34% |
| 2022 | -7.36 Billion KRW | 46.94% |
| 2021 | -13.87 Billion KRW | -2098.17% |
| 2020 | 694.51 Million KRW | -93.04% |
| 2019 | 9.98 Billion KRW | 556.35% |
| 2018 | -2.18 Billion KRW | -172.21% |
| 2017 | 3.02 Billion KRW | -44.46% |
| 2016 | 5.45 Billion KRW | 8.05% |
| 2015 | 5.04 Billion KRW | -27.64% |
| 2014 | 6.97 Billion KRW | 0.87% |
| 2013 | 6.91 Billion KRW | 111.66% |
| 2012 | 3.26 Billion KRW | -20.02% |
| 2011 | 4.08 Billion KRW | 910.21% |
| 2010 | 404.44 Million KRW | 126.95% |
| 2009 | -1.5 Billion KRW | -190.28% |
| 2008 | 1.66 Billion KRW | 122.36% |
| 2007 | -7.43 Billion KRW | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | 4.6 Billion KRW | 77.2% |
| 2024 Q2 | 1.2 Billion KRW | -73.72% |
| 2024 Q3 | 1.32 Billion KRW | 9.16% |
| 2023 Q4 | 2.59 Billion KRW | 711.24% |
| 2023 Q1 | 318.26 Million KRW | 111.65% |
| 2023 Q2 | -348.1 Million KRW | -209.37% |
| 2023 FY | 3.11 Billion KRW | 142.34% |
| 2023 Q3 | 320.11 Million KRW | 191.96% |
| 2022 Q3 | -2.32 Billion KRW | -55.16% |
| 2022 FY | -7.36 Billion KRW | 46.94% |
| 2022 Q1 | -951.19 Million KRW | 66.46% |
| 2022 Q2 | -1.49 Billion KRW | -57.33% |
| 2022 Q4 | -2.73 Billion KRW | -17.63% |
| 2021 Q3 | -4.15 Billion KRW | 15.49% |
| 2021 Q4 | -2.83 Billion KRW | 31.81% |
| 2021 FY | -13.87 Billion KRW | -2098.17% |
| 2021 Q1 | -1.95 Billion KRW | 32.72% |
| 2021 Q2 | -4.92 Billion KRW | -151.12% |
| 2020 Q3 | -541.41 Million KRW | -139.91% |
| 2020 Q4 | -2.91 Billion KRW | -438.05% |
| 2020 FY | 694.51 Million KRW | -93.04% |
| 2020 Q1 | 2.47 Billion KRW | 654.36% |
| 2020 Q2 | 1.35 Billion KRW | -45.29% |
| 2019 Q3 | 3.68 Billion KRW | -18.77% |
| 2019 FY | 9.98 Billion KRW | 556.35% |
| 2019 Q1 | 2.21 Billion KRW | 12.96% |
| 2019 Q2 | 4.53 Billion KRW | 104.6% |
| 2019 Q4 | -447.25 Million KRW | -112.15% |
| 2018 Q2 | -2.51 Billion KRW | -313.91% |
| 2018 Q1 | 1.17 Billion KRW | 165.97% |
| 2018 FY | -2.18 Billion KRW | -172.21% |
| 2018 Q4 | 1.96 Billion KRW | 169.86% |
| 2018 Q3 | -2.8 Billion KRW | -11.44% |
| 2017 Q4 | -1.78 Billion KRW | -299.94% |
| 2017 Q2 | 1.2 Billion KRW | -55.71% |
| 2017 Q1 | 2.71 Billion KRW | 520.55% |
| 2017 Q3 | 892.86 Million KRW | -25.82% |
| 2017 FY | 3.02 Billion KRW | -44.46% |
| 2016 Q3 | 2.36 Billion KRW | 7.35% |
| 2016 Q4 | -646.22 Million KRW | -127.3% |
| 2016 FY | 5.45 Billion KRW | 8.05% |
| 2016 Q1 | 1.52 Billion KRW | -10.64% |
| 2016 Q2 | 2.2 Billion KRW | 44.36% |
| 2015 Q2 | 601.49 Million KRW | -65.75% |
| 2015 Q4 | 1.7 Billion KRW | 74.36% |
| 2015 Q3 | 980.46 Million KRW | 63.01% |
| 2015 FY | 5.04 Billion KRW | -27.64% |
| 2015 Q1 | 1.75 Billion KRW | -17.62% |
| 2014 Q4 | 2.13 Billion KRW | 84.56% |
| 2014 Q3 | 1.15 Billion KRW | -0.52% |
| 2014 Q2 | 1.16 Billion KRW | -54.07% |
| 2014 Q1 | 2.52 Billion KRW | 287.83% |
| 2014 FY | 6.97 Billion KRW | 0.87% |
| 2013 FY | 6.91 Billion KRW | 111.66% |
| 2013 Q3 | 2.16 Billion KRW | -48.76% |
| 2013 Q2 | 4.22 Billion KRW | 125.58% |
| 2013 Q1 | 1.87 Billion KRW | 99.9% |
| 2013 Q4 | -1.34 Billion KRW | -162.18% |
| 2012 FY | 3.26 Billion KRW | -20.02% |
| 2012 Q4 | 936.92 Million KRW | -72.56% |
| 2012 Q3 | 3.41 Billion KRW | 110.02% |
| 2012 Q2 | 1.62 Billion KRW | 160.01% |
| 2012 Q1 | -2.7 Billion KRW | -456.1% |
| 2011 Q3 | 489 Million KRW | -41.81% |
| 2011 Q1 | 1.99 Billion KRW | 321.55% |
| 2011 Q4 | 760.77 Million KRW | 55.58% |
| 2011 Q2 | 840.43 Million KRW | -57.88% |
| 2011 FY | 4.08 Billion KRW | 910.21% |
| 2010 Q2 | 3.1 Billion KRW | 188.88% |
| 2010 Q1 | -3.49 Billion KRW | -833.51% |
| 2010 Q4 | -900.69 Million KRW | -153.19% |
| 2010 Q3 | 1.69 Billion KRW | -45.43% |
| 2010 FY | 404.44 Million KRW | 126.95% |
| 2009 FY | -1.5 Billion KRW | -190.28% |
| 2009 Q4 | 476.05 Million KRW | 254.33% |
| 2009 Q3 | -308.46 Million KRW | 81.17% |
| 2009 Q2 | -1.63 Billion KRW | -5285.62% |
| 2009 Q1 | -30.41 Million KRW | -107.32% |
| 2008 Q3 | -258.99 Million KRW | -127.77% |
| 2008 Q4 | 415.56 Million KRW | 260.45% |
| 2008 Q2 | 932.62 Million KRW | 122.96% |
| 2008 FY | 1.66 Billion KRW | 122.36% |
| 2008 Q1 | 418.28 Million KRW | 123.54% |
| 2007 Q2 | -7.25 Billion KRW | -2260.59% |
| 2007 Q3 | 1.16 Billion KRW | 116.1% |
| 2007 Q1 | 335.77 Million KRW | 0.0% |
| 2007 Q4 | -1.77 Billion KRW | -252.12% |
| 2007 FY | -7.43 Billion KRW | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 364.53 Million KRW | -755.165% |
| Dong-A Socio Holdings Co., Ltd. | 76.88 Billion KRW | 95.945% |
| Ildong Holdings Co., Ltd. | -79.56 Billion KRW | 103.918% |
| HANDOK Inc. | 12.57 Billion KRW | 75.217% |
| Kukje Pharma Co., Ltd. | -1.98 Billion KRW | 256.72% |
| Yuhan Corporation | 74.56 Billion KRW | 95.819% |
| Dong-A ST Co., Ltd. | 11.17 Billion KRW | 72.112% |
| SAMSUNG PHARM. Co., LTD. | -18.04 Billion KRW | 117.278% |
| Hanmi Pharm. Co., Ltd. | 224.88 Billion KRW | 98.614% |
| Hanall Biopharma Co.,Ltd | 3.05 Billion KRW | -2.007% |
| Ilyang Pharmaceutical Co.,Ltd | 14.35 Billion KRW | 78.277% |
| Dong Sung Bio Pharm.Co.,Ltd. | 596.4 Million KRW | -422.699% |
| MYUNGMOON Pharm co.,Ltd | 963.76 Million KRW | -223.46% |
| Hana Pharm Co., Ltd. | 27.03 Billion KRW | 88.468% |
| Yuyu Pharma, Inc. | 364.53 Million KRW | -755.165% |
| Ilsung Pharmaceuticals Co., Ltd. | -7.75 Billion KRW | 140.193% |
| REYON Pharmaceutical Co., Ltd. | 4.03 Billion KRW | 22.715% |
| Aprogen pharmaceuticals,Inc. | -69.95 Billion KRW | 104.457% |
| JW Holdings Corporation | 143.66 Billion KRW | 97.83% |
| Ildong Pharmaceutical Co., Ltd. | -53.41 Billion KRW | 105.836% |
| Chong Kun Dang Pharmaceutical Corp. | 246.59 Billion KRW | 98.736% |
| JW Pharmaceutical Corporation | 100.3 Billion KRW | 96.892% |
| Shin Poong Pharm.Co.,Ltd. | -47.39 Billion KRW | 106.578% |
| Hyundai Pharmaceutical Co., Ltd. | 6.92 Billion KRW | 54.996% |
| Samil Pharmaceutical Co.,Ltd | 6.47 Billion KRW | 51.825% |
| Jeil Pharmaceutical Co.,Ltd | 8.73 Billion KRW | 64.297% |
| Yuyu Pharma, Inc. | 364.53 Million KRW | -755.165% |
| Kwang Dong Pharmaceutical Co., Ltd. | 48.76 Billion KRW | 93.608% |
| Daewoong pharmaceutical Co.,Ltd | 133.4 Billion KRW | 97.663% |
| JW Pharmaceutical Corporation | 100.3 Billion KRW | 96.892% |
| Yuhan Corporation | 74.56 Billion KRW | 95.819% |
| Jeil Pharma Holdings Inc | 20.92 Billion KRW | 85.099% |
| Suheung Co., Ltd. | 42.99 Billion KRW | 92.749% |
| JW Pharmaceutical Corporation | 100.3 Billion KRW | 96.892% |
| Samjin Pharmaceuticals Co., Ltd. | 20.48 Billion KRW | 84.782% |
| Korea United Pharm Inc. | 54.94 Billion KRW | 94.327% |
| CKD Bio Corp. | -20.15 Billion KRW | 115.469% |
| Daewon Pharmaceutical Co., Ltd. | 32.23 Billion KRW | 90.329% |
| Dongwha Pharm.Co.,Ltd | 25.3 Billion KRW | 87.679% |
| Whan In Pharm Co.,Ltd. | 32.52 Billion KRW | 90.415% |
| Shin Poong Pharm.Co.,Ltd. | -47.39 Billion KRW | 106.578% |
| Chong Kun Dang Holdings Corp. | 33.14 Billion KRW | 90.595% |
| Boryung Corporation | 68.26 Billion KRW | 95.434% |
| Bukwang Pharmaceutical Co., Ltd. | -37.49 Billion KRW | 108.314% |
| Ilyang Pharmaceutical Co.,Ltd | 14.35 Billion KRW | 78.277% |
| JW Lifescience Corporation | 32.09 Billion KRW | 90.286% |